JLJianfeng Li

Jianfeng Li

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Jianfeng Li has a total of 26 co-authors. Here are the top co-authors by number of shared publications:

  • Chengpeng Yu

    Department of General Surgery, The First Affiliated Hospital of Nanchang University, Nanchang, China

    1 shared publication
  • Daya Luo

    The MOE Basic Research and Innovation Center for the Targeted Therapeutics of Solid Tumors, Jiangxi Medical College, Nanchang University, Nanchang, 330031, China.

    1 shared publication
  • Dongdong Ru

    Department of General Surgery, Jincheng People’s Hospital, Jincheng 048026, China

    1 shared publication
  • Feng Zhu

    Department of General Surgery, Tianjin Medical University General Hospital, Tianjin 300052, China

    1 shared publication
  • Haiting Wan

    Department of General Surgery, The First Affiliated Hospital of Nanchang University, Nanchang, China

    1 shared publication
  • Hong-Xin Ai

    Jiangsu Province Key Laboratory for Molecular and Medical Biotechnology, Life Sciences College, Nanjing Normal University, Nanjing 210097, PR China

    1 shared publication

Latest Publications

  • Open Access

    Plasma DNA Integrity as a Prognostic Biomarker for Colorectal Cancer Chemotherapy

    by Feng Zhu, Jing Ma, Dongdong Ru, Ningning Wu, Yunhua Zhang, Huiyuan Li, Xiaoli Liu, Jianfeng Li, Huiling Zhang, Yue Xu, et al.

    Objectives. To verify whether the concentrations and integrity index of circulating cell-free DNA (cfDNA) in serum may be clinically useful for the progression monitoring of colorectal cancer (CRC) patients. Methods. Serum samples were collected from 76 primary CRC patients who underwent surgery, including 60 with chemotherapy and 43 with follow-up. Long (247bp) and short (115bp) DNA fragments in serum were detected by real-time quantitative PCR by amplifying the ALU repeats. Ten serum traditional biomarkers levels were detected by chemiluminescence immunoassay assay. Results. The median DNA integrity index (ALU247/ALU115) of serum DNA in the preoperative group was significantly higher than those in the postchemotherapy and the follow-up groups, while cfDNA concentration (ALU115) was significantly lower in the preoperative group compared with the postchemotherapy and the follow-up groups. CEA and CA242 were significantly lower in the postoperative group than in the preoperative group. Conclusions. Serum DNA integrity index (ALU247/115) may prove to be a promising candidate biomarker for prognostic prediction of CRC who underwent chemotherapy and during short-term follow-up.


  • Open Access

    The Prognostic Value of the MiR-200 Family in Colorectal Cancer: A Meta-analysis with 1882 Patients

    by Chengpeng Yu, Haiting Wan, Renfeng Shan, Wu Wen, Jianfeng Li, Daya Luo, Renhua Wan

    Background: MicroRNAs are small non-coding RNAs containing 18-22 nucleotides which play a role in RNA silencing and post-transcriptional regulation of their target genes. The MiR-200 family comprises miR-141, miR-200a, miR-200b, miR-200c and miR-429. Increasing evidence indicates that miR-200 microRNAs play a role in cancer metastasis. For example, miR-200 microRNAs were reported to influence the prognosis in colorectal cancer patients by regulating the expression of genes related to the epithelial-mesenchymal transition6. Previous studies have shown that the high expression of miR-200 microRNAs has an impact on the overall survival and Relapse-free Survival of CRC patients. However, the study results were inconsistent. Results: Data from a total of 1882 patients from 9 studies was included in the meta-analysis. Poorer Relapse-free Survival (RFS) was observed in patients with high expression levels of miR-200 microRNAs (HR=1.13, 95% CI 1.04-1.23). Additionally, subgroup analysis of sample types revealed a significant association between higher expression of the miR-200 family in the plasma and poorer OS (HR=1.23, 95% CI 1.08-1.41) and RFS (HR=2.39, 95% CI 1.20-4.77), which indicates that the miR-200 family can be used as an easily detectable biomarker for evaluation of the prognosis of patients with colorectal cancer. Conclusions: High expression levels of miR-200 microRNAs were associated with poor clinical outcomes in colorectal cancer patients. The miR-200 family can therefore potentially serve as a prognostic biomarker. Further studies should be performed to verify the clinical utility of the miR-200 family in colorectal cancer.


  • Molecular characterization of the canine cytokine TWEAK (CD255) and its receptor, Fn14 (CD266)

    by Jia-Xin Zhang, Ming Sang, Wei Zhao, Hong-Xin Ai, Yan Shui, Jian-Feng Li, Ren Song, Shuang-Quan Zhang